Abstract
Decentralized clinical trials (DCTs) extend trial activities beyond traditional sites, enhancing access, convenience, efficiency, and result generalizability. They are particularly promising for chronic conditions like diabetes and obesity, which require longer study durations to evaluate drug effects. However, decentralized data collection raises concerns about increased variability and potential biases. This paper presents a novel Bayesian integrated learning procedure to analyze dose-response relationships using longitudinal data from a phase II DCT that combines centralized and decentralized data collection. We generalize a parametric exponential decay model to handle mixed data sources and apply Bayesian spike-and-slab priors to address biases and uncertainties from decentralized measurements. Our model enables data-adaptive integration of information from both centralized and decentralized sources. Through simulations and sensitivity analyses, we show that the proposed approach achieves favorable performance across various scenarios. Notably, the method matches the efficiency of traditional trials when decentralized data collection introduces no additional variability or error. Even when such issues arise, it remains less biased and more efficient than naïve methods that rely solely on centralized data or simply pool data from both sources.